Both chemokines have been previously shown to promote the progression of PCa (35, 36), and Wang et al. (37) demonstrated that the CXCL5-CXCR2 axis plays an important role in the recruitment of MDSCs to prostatic tumors and that targeting it impairs disease progression. Here, CXCR2 is linked to prostate neoplasm.